Cross Country Healthcare (CCRN) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $315.1 million, down 29% year-over-year and 7% sequentially, mainly due to declines in travel nurse and allied staffing, while home care, physician staffing, and education segments showed strong momentum and now represent about 30% of total revenue, up from 10% in 2021.

• Net income attributable to common stockholders was $2.6 million, down from $12.8 million in Q3 2023.

• Adjusted EBITDA was $10.3 million (3.3% margin), reflecting lower operating leverage and gross margin pressure.

• Technology investments, particularly the Intellify platform, are driving differentiation and operational efficiency.

• Repurchased over 800,000 shares for $11.9 million in Q3; ended quarter with $64 million cash and no debt.

Financial highlights

• Q3 2024 consolidated revenue was $315.1 million, down 7% sequentially and 29% year-over-year, with gross profit margin at 20.4%, down 40 bps sequentially and 160 bps year-over-year due to bill pay spread compression.

• Adjusted EPS was $0.12, at the high end of guidance, aided by lower stock compensation, discrete tax benefits, and fewer shares outstanding.

• SG&A expense was $54 million, down 10% sequentially and 22% year-over-year, driven by headcount reductions and process efficiencies.

• Net cash provided by operating activities was $7.5 million in Q3 and $95.9 million for the nine months ended September 30, 2024.

• Credit loss expense for Q3 2024 was $1.5 million, with a $19.4 million credit loss in Q2 2024 due to a large customer bankruptcy.

Outlook and guidance

• Q4 2024 revenue is expected between $300–$310 million, a 2–5% sequential decline and 25–28% year-over-year decline, mainly due to the absence of a labor disruption that benefited Q3.

• Adjusted EBITDA guidance for Q4 is $11–$13 million (approx. 4% margin), with adjusted EPS of $0.10–$0.14.

• Gross margin is expected at 21% for Q4, with stable bill rates and continued cost management.

• The company aims for high single-digit adjusted EBITDA margin long-term, but expects mid-single digits near term.

• Guidance excludes impacts from future M&A, debt changes, or significant share repurchases.